ATE331703T1 - Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln - Google Patents
Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormittelnInfo
- Publication number
- ATE331703T1 ATE331703T1 AT01926512T AT01926512T ATE331703T1 AT E331703 T1 ATE331703 T1 AT E331703T1 AT 01926512 T AT01926512 T AT 01926512T AT 01926512 T AT01926512 T AT 01926512T AT E331703 T1 ATE331703 T1 AT E331703T1
- Authority
- AT
- Austria
- Prior art keywords
- antitumor agents
- treating tumors
- retinoid compounds
- compounds along
- rar alpha
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- -1 RETINOID COMPOUNDS Chemical class 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 101001100204 Homo sapiens Ras-related protein Rab-40A-like Proteins 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102100038416 Ras-related protein Rab-40A-like Human genes 0.000 abstract 1
- 101100236975 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GAL11 gene Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54214800A | 2000-04-04 | 2000-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE331703T1 true ATE331703T1 (de) | 2006-07-15 |
Family
ID=24162539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01926512T ATE331703T1 (de) | 2000-04-04 | 2001-04-02 | Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6387950B2 (https=) |
| EP (2) | EP1650188A1 (https=) |
| JP (1) | JP2003534246A (https=) |
| AT (1) | ATE331703T1 (https=) |
| AU (1) | AU2001253045A1 (https=) |
| CA (1) | CA2405136C (https=) |
| DE (1) | DE60121145T2 (https=) |
| ES (1) | ES2267754T3 (https=) |
| TW (1) | TWI281911B (https=) |
| WO (1) | WO2001074759A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6903121B1 (en) | 2000-08-17 | 2005-06-07 | Allergan, Inc. | Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| SI1324970T1 (sl) * | 2000-10-02 | 2009-02-28 | Hoffmann La Roche | Retinoidi za zdravljenje emfizema |
| EP1935869A1 (en) * | 2000-10-02 | 2008-06-25 | F. Hoffmann-La Roche Ag | Retinoids for the treatment of emphysema |
| US6620963B1 (en) | 2002-09-19 | 2003-09-16 | Allergan, Inc. | TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY |
| WO2005093426A2 (en) * | 2004-03-26 | 2005-10-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara) |
| CN101316583A (zh) | 2005-09-30 | 2008-12-03 | 生命医药公司 | 用特异性rxr激动剂治疗癌症 |
| WO2012125749A2 (en) * | 2011-03-14 | 2012-09-20 | Io Therapeutics, Inc. | INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS |
| WO2013090616A1 (en) | 2011-12-13 | 2013-06-20 | Io Therapeutics, Inc. | Autoimmune disorder treatment using rxr agonists |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| PL3277272T3 (pl) | 2015-03-31 | 2022-01-24 | Syros Pharmaceuticals, Inc. | Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego |
| CN116077626A (zh) | 2015-10-31 | 2023-05-09 | Io治疗公司 | 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱 |
| EP3380086B1 (en) | 2015-11-25 | 2021-10-13 | IO Therapeutics, Inc. | Cyp26-resistant rar-alpha selective agonists in the treatment of cancer |
| US10835507B2 (en) | 2016-03-10 | 2020-11-17 | Io Therapeutics, Inc. | Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones |
| KR102605349B1 (ko) | 2016-03-10 | 2023-11-22 | 아이오 테라퓨틱스, 인크. | Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료 |
| WO2017177167A1 (en) | 2016-04-08 | 2017-10-12 | Syros Pharmaceuticals, Inc. | Rara agonists for the treatment of aml and mds |
| US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
| WO2019014468A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY |
| US10363272B2 (en) * | 2017-08-31 | 2019-07-30 | Io Therapeutics, Inc. | RAR selective agonists in combination with immune modulators for cancer immunotherapy |
| CA3076373A1 (en) | 2017-09-20 | 2019-03-28 | Io Therapeutics, Inc. | Treatment of disease with esters of selective rxr agonists |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| CA3242047A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist in treating drug resistant her2+ cancers |
| AU2022408160A1 (en) | 2021-12-07 | 2024-06-06 | Board Of Regents, The University Of Texas System | Use of an rxr agonist and taxanes in treating her2+ cancers |
| CN114703227B (zh) * | 2022-01-27 | 2023-11-10 | 中国科学院生态环境研究中心 | 基于MCF-7细胞系构建的RARα效应物体外筛选方法 |
| JP2025521810A (ja) | 2022-06-27 | 2025-07-10 | アイオー セラピューティクス インコーポレイテッド | テトラヒドロナフタレノール類の合成およびその用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4001618B2 (ja) * | 1991-12-18 | 2007-10-31 | ザ ソールク インスチチュート フォア バイオロジカル スタディズ | レチノイド受容体によって仲介される過程の修飾方法およびそれに有用な化合物 |
| US5675024A (en) * | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
| US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
-
2001
- 2001-03-30 TW TW090107695A patent/TWI281911B/zh not_active IP Right Cessation
- 2001-04-02 EP EP05025970A patent/EP1650188A1/en not_active Withdrawn
- 2001-04-02 ES ES01926512T patent/ES2267754T3/es not_active Expired - Lifetime
- 2001-04-02 EP EP01926512A patent/EP1268405B1/en not_active Expired - Lifetime
- 2001-04-02 JP JP2001572454A patent/JP2003534246A/ja active Pending
- 2001-04-02 DE DE60121145T patent/DE60121145T2/de not_active Expired - Lifetime
- 2001-04-02 AT AT01926512T patent/ATE331703T1/de not_active IP Right Cessation
- 2001-04-02 AU AU2001253045A patent/AU2001253045A1/en not_active Abandoned
- 2001-04-02 US US09/824,111 patent/US6387950B2/en not_active Expired - Fee Related
- 2001-04-02 WO PCT/US2001/010410 patent/WO2001074759A1/en not_active Ceased
- 2001-04-02 CA CA002405136A patent/CA2405136C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2267754T3 (es) | 2007-03-16 |
| JP2003534246A (ja) | 2003-11-18 |
| DE60121145T2 (de) | 2007-05-31 |
| CA2405136A1 (en) | 2001-10-11 |
| EP1268405A1 (en) | 2003-01-02 |
| US20010039293A1 (en) | 2001-11-08 |
| WO2001074759A1 (en) | 2001-10-11 |
| AU2001253045A1 (en) | 2001-10-15 |
| TWI281911B (en) | 2007-06-01 |
| US6387950B2 (en) | 2002-05-14 |
| EP1268405B1 (en) | 2006-06-28 |
| DE60121145D1 (de) | 2006-08-10 |
| CA2405136C (en) | 2009-06-16 |
| EP1650188A1 (en) | 2006-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE331703T1 (de) | Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| CY1108367T1 (el) | Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου | |
| FI935306A7 (fi) | Puhdistettujen, pintaa modifioivien aineiden käyttö estämään hiukkasten kasautumista steriloinnin aikana | |
| DE60016393D1 (de) | Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe | |
| JP2003522724A5 (https=) | ||
| KR900015729A (ko) | 흥분성 아미노산 길항제 | |
| LV10860A (lv) | Fenilalkilaminu iegusanas panemiens | |
| DK0694545T3 (da) | Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder | |
| EA199901075A1 (ru) | Лечение резистентности к инсулину средствами, стимулирующими секрецию гормона роста | |
| RU94044456A (ru) | Средство для подавления дисфункционального маточного кровотечения | |
| ATE187642T1 (de) | Verwendund von norastemizol zur behandlung der allergischen rhinitis | |
| KR880009948A (ko) | 항 알레르기 및 항 염증제로서 용도를 갖는 신규의 나프탈렌 유도체 | |
| NO923199L (no) | Terapeutiske forbindelser | |
| RU94045271A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера | |
| FI923664A0 (fi) | Piperidinderivat. | |
| NO20014240D0 (no) | C16-umettede FP-selektive prostaglandinanaloger | |
| NO923198D0 (no) | Terapeutiske midler | |
| KR927002224A (ko) | 항종양효과증강제 및 항종양제 | |
| TR200102009T2 (tr) | Serebral işlemi profilaksı ve tedavisi için formül I'e göre bileşiklerin kullanımı | |
| ES2049703T1 (es) | Derivados de acidos biliares sulfurados. | |
| ES2073871T3 (es) | Tiazolidin-2,4-dionas en el tratamiento de la hipertension. | |
| KR910007526A (ko) | 인터류킨-1 생합성 억제제로의 3-치화된-2-옥신돌 유도체 | |
| PT985414E (pt) | Metodo de tratamento de glaucoma e retinopatia isquemica | |
| RU96113185A (ru) | Раствор для лечения заболеваний и повреждений роговицы "кератан-с" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |